Although SCA was rare in a Korean population-based study -- occurring in 0.08% of over 6.8 million adults under age 40 -- it was more likely in those whose routine lab results flagged proteinuria ...

A new study published in the journal of BMC Nephrology showed that in individuals with primary membranous nephropathy (PMN), ...

Proteinuria is associated with a higher risk of sudden cardiac arrest in young adults, especially with chronic kidney disease ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS ...

Sudden cardiac arrest survival rates are only around 10%, but new research spotted a test that may flag warning in young adulthood.

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...

When the U.S. Food and Drug Administration (FDA) approved rosuvastatin, early reports indicated that it could cause blood ...